MATEON THERAPEUTICS, INC. (OTCMKTS:MATN) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure. |
On April24, 2017, Mateon Therapeutics, Inc. (the Company) posted
a corporate presentation to its website, which the Company plans
to present at various investor and analyst meetings. The
presentation is attached hereto as Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit
99.1 hereto, is being furnished and shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended, nor shall it be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, as amended, except as expressly set forth in such filing.
| Item9.01 | Financial Statements and Exhibits. |
The following exhibit is furnished with this report:
|
Exhibit Number |
Description | |
| 99.1 | Corporate Presentation prepared as of April24, 2017. |
About MATEON THERAPEUTICS, INC. (OTCMKTS:MATN)
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA. MATEON THERAPEUTICS, INC. (OTCMKTS:MATN) Recent Trading Information
MATEON THERAPEUTICS, INC. (OTCMKTS:MATN) closed its last trading session 00.000 at 0.780 with 988,527 shares trading hands.